<DOC>
	<DOCNO>NCT00595140</DOCNO>
	<brief_summary>The purpose study investigate efficacy acute additional application somatostatin analogue octreotide 100Âµg s.c. dopamine agonist cabergoline 0.5mg p.o . receptor antagonist pegvisomant 6 9 hour profile reduce endogenous growth hormone patient acromegaly stable pegvisomant therapy .</brief_summary>
	<brief_title>Acute Application Pegvisomant Octreotide Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>patient acromegaly currently stable pegvisomant therapy patient diabetes mellitus may include . Glucose level must control regularly throughout study patient must cotreated medication acromegaly radiotherapy within last 2 year relevant acute disease history hypersensitivity use drug pregnancy lactation abnormal baseline finding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Acromegaly ,</keyword>
	<keyword>growth hormone receptor antagonist ,</keyword>
	<keyword>somatostatin analogue ,</keyword>
	<keyword>combine medical treatment ,</keyword>
	<keyword>acute effect ,</keyword>
	<keyword>endogenous GH</keyword>
</DOC>